Pharma Penny Stock Under Rs 50 Approves FY25 Audited Results; Recommended Rs 0.10 Dividend & Approves Rs 37.22 Cr Acquisition in Trimax Bio Sciences
From Rs 34.51 per share (52-week low) to Rs 53.59 per share, the stock is up by 55.3 per cent.
Today, shares of Sigachi Industries Ltd gained 1.77 per cent to Rs 53.59 per share from its previous closing of Rs 52.66 per share. The company has a market cap of Rs 1,787 crore and has delivered good profit growth of 28 per cent CAGR over the last 5 years. From Rs 34.51 per share (52-week low) to Rs 53.59 per share, the stock is up by 55.3 per cent.
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q4FY25) and annual results (FY25). According to quarterly results, revenue increased by 23 per cent to Rs 128.21 crore, EBITDA increased by 30 per cent to Rs 30.75 crore and net profit increased by 7 per cent to Rs 16.17 crore in Q4FY25 compared to Q4FY24. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24. The Board recommended a final dividend of Re 0.10 per share, subject to approval of members at the ensuing Annual General Meeting.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
Sigachi Industries Limited acquired 1,07,17,672 equity shares in Trimax Bio Sciences Private Limited for Rs 37.22 crore, converting an existing advance/loan into equity, subject to shareholder approval. This comes as Sigachi's subsidiary, Trimax Bio Sciences Pvt Ltd, recently received a Certificate of Suitability (CEP) for Metformin Hydrochloride from the EDQM, a significant milestone that allows Trimax to export this crucial API to Europe and other recognised markets. This certification not only strengthens Sigachi's position in regulated pharmaceutical landscapes but also aligns with its strategic goal of expanding into regions with high demand for essential pharmaceutical ingredients like Metformin, which is widely used for type 2 diabetes.
Disclaimer: The article is for informational purposes only and not investment advice.